Page last updated: 2024-12-05

practolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Practolol is a beta blocker that was developed in the 1960s for the treatment of hypertension and angina. It was initially considered a promising drug due to its selective action on beta1 receptors, which are found in the heart. However, practolol was later withdrawn from the market due to its association with serious side effects, including sclerosing peritonitis, a rare and potentially fatal condition. The synthesis of practolol involves several steps, starting with the reaction of 2-hydroxy-3-aminopropane with 4-chloro-2-nitrobenzaldehyde. This intermediate compound is then reduced to the corresponding amine, which is reacted with propranolol to yield practolol. Practolol's effects are primarily due to its ability to block beta1 receptors in the heart, leading to decreased heart rate, contractility, and blood pressure. The study of practolol has been important in advancing our understanding of beta blockers and their potential side effects. The development of sclerosing peritonitis associated with practolol highlighted the need for rigorous safety testing of new drugs.'

Practolol: A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

practolol : N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythmias. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol: inhibits glucosylceramide synthase; do not confuse with PPPP [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4883
CHEMBL ID6995
CHEBI ID258351
SCHEMBL ID39925
MeSH IDM0017428
PubMed CID9868804
SCHEMBL ID295611
MeSH IDM0017428

Synonyms (124)

Synonym
LS-12647
MLS002153779
smr001233163
BRD-A41304429-001-04-9
AKOS002685374
gtpl555
KBIO1_000901
DIVK1C_000901
n-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide
n-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide
einecs 229-712-1
ay 21011
ccris 1089
1-(4-acetamidophenoxy)-3-isopropylamino-2-propanol
acetanilide, 4'-(2-hydroxy-3-(isopropylamino)propoxy)-
dalzic
teranol
praktololu [polish]
ici-50172
ici 50172
acetamide, n-(4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)-
eraldin
n-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide
practololum [inn-latin]
4'-(2-hydroxy-3-(isopropylamino)propoxy)acetanilide
practololo [dcit]
SPECTRUM5_001123
BSPBIO_000363
BPBIO1_000401
PRESTWICK3_000332
D05587
practolol (usan)
OPREA1_095524
IDI1_000901
chembl6995 ,
practolol,(-)
practolol,(+)
n-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide
bdbm25749
AB00052459
practolol
6673-35-4
DB01297
(+/-)-practolol
NCGC00024810-02
KBIO2_007070
KBIO2_001934
KBIOSS_001934
KBIOGR_001497
KBIO2_004502
PRESTWICK1_000332
PRESTWICK0_000332
SPBIO_001504
SPECTRUM4_000859
SPECTRUM2_001572
NINDS_000901
SPBIO_002284
PRESTWICK2_000332
NCGC00024810-03
HMS2089I09
L000491
[3-(4-acetylamino-phenoxy)-2-hydroxy-propyl]-isopropyl-ammonium
ay-21011
i.c.i.-50,172
i.c.i. 50,172
ay-21,011
HMS502N03
4'-[2-hydroxy-3-(isopropylamino)propoxy]acetanilide
n-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]acetamide
dl-practolol
rac practolol
HMS1569C05
n-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
practololum
chebi:258351 ,
NCGC00024810-04
HMS2096C05
n-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide
EN300-72170
dtxsid0021179 ,
tox21_110928
dtxcid001179
HMS2233K23
CCG-39350
sug9176grw ,
unii-sug9176grw
praktololu
practololo
practolol [usan:inn:ban]
FT-0673986
HMS3374G04
practolol [inn]
practolol [usan]
dl-4'-(2-hydroxy-3-(isopropylamino)propoxy)acetanilide
practolol [who-dd]
practolol [mart.]
practolol [mi]
AKOS016054902
SCHEMBL39925
tox21_110928_1
NCGC00024810-07
acetamide, n-[4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-
4-[2-hydroxy-3-(isopropylamino)propoxy]-acetanilide
acetanilide, 4'-[2-hydroxy-3-(isopropylamino)propoxy]-
n-(4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)acetamide #
practalol
DURULFYMVIFBIR-UHFFFAOYSA-N
STL489279
SR-01000597449-1
SR-01000597449-4
SR-01000597449-2
sr-01000597449
practolol, >=95% (hplc)
SBI-0051937.P002
HMS3713C05
Z274728816
n-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide ,
Q7237376
BRD-A41304429-001-12-2
HY-119802
CS-0078043
1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol
SCHEMBL295611
n-(1-hydroxy-1-phenyl-3-pyrrolidin-1-ylpropan-2-yl)hexadecanamide

Research Excerpts

Overview

Practolol is a cardio-selective beta-blocking agent with an intrinsic sympathomimetic action, but devoid of local anaesthetic effect. prolonged use may result in the appearance of untoward side-effects, notably ocular symptoms and deafness.

ExcerptReferenceRelevance
"Practolol is a cardio-selective beta-blocking agent with an intrinsic sympathomimetic action, but devoid of local anaesthetic effect."( Practolol in acute myocardial infarction.
Barber, JM; Boyle, DM; Chaturvedi, NC; Singh, N; Walsh, MJ, 1976
)
2.42
"Practolol ('Eraldin') is a beta-blocking agent whose prolonged use may result in the appearance of untoward side-effects, notably ocular symptoms, skin rashes and deafness. "( Practolol and deafness.
Ballantyne, JC; Hammond, VT; Jones, RF; Wright, D, 1977
)
3.14

Effects

ExcerptReferenceRelevance
"Practolol has been linked with a lupus syndrome characterized by biological abnormalities and eventually clinical signs; later on, other beta-blocking agents have been able to induce such manifestations."( [Review: beta-blocking agents in dermatology (author's transl)].
Bourlond, A; Clerens, A; Defresne, C; Guilmot-Bruneau, MM, 1981
)
0.98

Treatment

Practolol pretreatment increased the dose of digoxin required to produce arrhythmias and markedly altered the pattern of toxicity, but did not alter the lethal dose. Practolol-treated dogs showed a tear flow reduction.

ExcerptReferenceRelevance
"Practolol pretreatment increased the dose of digoxin required to produce arrhythmias and markedly altered the pattern of toxicity, but did not alter the lethal dose."( Effect of cardiac beta-adrenergic blockade or denervation on cardiotoxicity of digoxin and an aminosugar cardenolide.
Caldwell, RW; Nash, CB; Puryear, SK,
)
0.85
"Practolol-treated dogs showed a tear flow reduction: histopathological examination showed lymphocytic infiltration in the lacrymal glands and electroretinogram showed a decrease in the amplitudes of the A + B-wave."( Evaluation of ocular toxicity of two beta blocking drugs, carteolol and practolol, in beagle dogs.
Hiyama, T; Nakajima, A; Ohkawa, T; Tanaka, N, 1983
)
1.22
"Practolol pretreatment abolished the increase in plasma cyclic AMP concentration and reduced the rise in cardiac output during hypoxemia."( Effects of arterial hypoxemia and splenic nerve stimulation on myocardial adenosine 3',5'-Monophosphate in dogs.
Liang, C; Volicer, L, 1975
)
0.98
"Practolol treatment induced a significant BP reduction, while the addition of salbutamol failed to give any further decrease."( Antihypertensive effect of beta-1 receptor blockade and beta-2-receptor stimulation in essential hypertension.
Andersson, O; Berglund, G, 1975
)
0.98
"If practolol treatment failed, the patient was given 5 mg of verapamil half an hour later, and vice versa."( Comparison of verapamil and practolol in paroxysmal supraventricular tachycardia.
Härtel, G; Hartikainen, M, 1976
)
1.06

Toxicity

Practolol did not alter the toxic dose of ASI-254 and produced little change in the pattern of cardiotoxicity. Both control and practolol-treated dogs died in cardiac standstill.

ExcerptReferenceRelevance
" Adverse and potentially specific reactions to individual beta-blocking agents."( Side effects and contraindications of beta-receptor blocking agents.
Lydtin, H, 1977
)
0.26
" The effect of pretreatment with five different beta-adrenoceptor blocking drugs (propranolol, alprenolol, practolol, metoprolol or tolamolol), p physostigmine, or atropine on these toxic actions of doxepin was investigated."( Effect of beta-adrenoceptor blocking drugs, physostigmine, and atropine on the toxicity of doxepin in mice.
Elonen, E, 1975
)
0.47
" To be able to conclude about a possible causal relationship between a drug and such a state with as short a delay in time as possible, the collection and analysis of adverse events during the total clinical trial program of a drug is mandatory."( Safety in clinical trials.
Wallander, MA, 1990
)
0.28
" Practolol did not alter the toxic dose of ASI-254 and produced little change in the pattern of cardiotoxicity; both control and practolol-treated dogs died in cardiac standstill."( Effect of cardiac beta-adrenergic blockade or denervation on cardiotoxicity of digoxin and an aminosugar cardenolide.
Caldwell, RW; Nash, CB; Puryear, SK,
)
1.04
"0 microM), while nearly completely blocking glucosylceramide synthesis, was not toxic and did not increase cellular ceramide levels."( Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity.
Ladisch, S; Olshefski, RS, 2001
)
0.31

Pharmacokinetics

practolol elimination was impaired in animals with experimental glomerulonephritis. Significant lengthening of the half-life of the beta-phase, with marked decrease of body clearance and diminution of the drug concentration decrease in plasma.

ExcerptReferenceRelevance
" Pharmacokinetic data were obtained in hypertensive male patients (4) after treatment with 14C-radioactively labelled acebutolol hydrochloride."( [Pharmacokinetics of acebutolol].
Collins, RF, 1975
)
0.25
" The results obtained demonstrated that the practolol elimination was impaired in animals with experimental glomerulonephritis: significant lengthening of the half-life of the beta-phase, with marked decrease of the body clearance and diminution of the drug concentration decrease in plasma."( Pharmacokinetics of practolol in the rabbit with experimental glomerulonephritis.
Desager, JP; Harvengt, C; Vanderbist, M, 1975
)
0.84
" Betaxolol (Kerlon, 8) was found to exhibit an appropriate preclinical pharmacological and human pharmacokinetic profile (elevated oral bioavailability and prolonged plasma half-life) for the treatment of chronic cardiovascular diseases such as hypertension and angina."( Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.
Binet, JL; Cavero, IG; Lefèvre-Borg, F; Manoury, PM; Rousseau, J, 1987
)
0.27
" Prenalterol was extensively distributed to extravascular tissues with a half-life of the distribution phase close to 7 min."( Pharmacokinetic studies in man of the selective beta 1-adrenoceptor agonist, prenalterol.
Graffner, C; Hoffmann, KJ; Johnsson, G; Lundborg, P; Rönn, O, 1981
)
0.26
"1 The speed of onset of the pharmacodynamic activity of intravenous propranolol, practolol, oxprenolol and metoprolol was determined, using attenuation of isoprenaline-induced tachycardia as the end-point, in 16 patients with clinically coronary heart disease."( Speed of onset of pharmacodynamic activity of propranolol, practolol, oxprenolol and metoprolol after intravenous infection in man.
Lochan, R; Silke, B; Taylor, SH, 1981
)
0.73
" The half-life of the elimination phase is close to 2 hours."( Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure.
Rönn, O, 1982
)
0.26

Compound-Compound Interactions

ExcerptReferenceRelevance
" It is concluded that the doses employed both of propranolol and practolol had a good and approximately equal antihypertensive effect when combined with chlorthalidone treatment."( Comparison of the antihypertensive effect of propranolol and practolol combined with chlorthalidone.
Boer, P; Geyskes, GG; Mees, EJ; Stutterheim, A, 1975
)
0.73
" When 'C7/3-phthalimido-propyl' was combined with competitive antagonists such as (+)-benzetimide, atropine or homatropine the degree of antagonism was greater than expected for combination of 2 competitive antagonists."( Antimuscarinic action of an alkane-bis-ammonium compound alone and in combination with (+)-benzetimide.
Mitchelson, F,
)
0.13
" In the current paper, this new extraction technique was combined with liquid chromatography-mass spectrometry (LC-MS) for the first time."( Liquid-phase microextraction based on carrier mediated transport combined with liquid chromatography-mass spectrometry. New concept for the determination of polar drugs in a single drop of human plasma.
Anthonsen, HS; Ho, TS; Pedersen-Bjergaard, S; Rasmussen, KE; Reubsaet, JL, 2005
)
0.33

Bioavailability

ExcerptReferenceRelevance
" There was no difference with either drug between the two age-groups in the mean absorption rate constant and the time at which maximum concentration in the plasma occurred."( The effect of ageing on drug absorption from the gut.
Castleden, CM; Raymond, K; Volans, CN, 1977
)
0.26
" Analysis of the results of the propranolol study suggests that an increase in the rate of absorption combined with saturation of first pass extraction may account for the increased plasma concentrations of unchanged propranolol found in coeliac disease."( Absorption of propranolol and practolol in Coeliac disease.
Kaye, CM; Parsons, RL; Raymond, K; Trounce, JR; Turner, P, 1976
)
0.54
" Betaxolol (Kerlon, 8) was found to exhibit an appropriate preclinical pharmacological and human pharmacokinetic profile (elevated oral bioavailability and prolonged plasma half-life) for the treatment of chronic cardiovascular diseases such as hypertension and angina."( Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.
Binet, JL; Cavero, IG; Lefèvre-Borg, F; Manoury, PM; Rousseau, J, 1987
)
0.27
" The drug was well absorbed from the gastrointestinal tract and most of the administered radioactivity was excreted in urine from all species within 24 hr."( The metabolic disposition of the selective beta 1-adrenoceptor agonist prenalterol in mice, rats, dogs, and humans.
Arfwidsson, A; Borg, KO; Hoffmann, KJ,
)
0.13
" The extent of bioavailability after administration of prenalterol as a solution is about 25% of an intravenous dose."( Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure.
Rönn, O, 1982
)
0.26
" Oral bioavailability averaged 33% and was independent of dose."( Cardioselectivity of prenalterol and isoproterenol.
Bobik, A; Hargreaves, M; Jennings, G; Korner, P; Oddie, C, 1983
)
0.27
" The new methodology may, therefore, be used for fast bioavailability screening of virtual libraries having millions of molecules."( Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
Ertl, P; Rohde, B; Selzer, P, 2000
)
0.31
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" To show the importance of physicochemical properties, the classic QSAR and CoMFA of neonicotinoids and prediction of bioavailability of pesticides in terms of membrane permeability in comparison with drugs are described."( Importance of physicochemical properties for the design of new pesticides.
Akamatsu, M, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Serological studies in 22 patients presenting with ocular disease attributable to dosage with the beta-blocking agent practolol revealed a raised incidence of antinuclear antibodies. In the dosage used in both studies, practiseolol significantly improved the exercise tolerance and reduced the ischaemic manifestations. Response to practoll was maximum within 15 minutes and was not improved by additional dosage sufficient to raise serum levels.

ExcerptRelevanceReference
" Drug dosage was selected to be proportionate to beta-adrenoreceptor-blocking potency; d-propranolol dosage equalled approximately that of racemic propranolol."( The antihypertensive action of several beta-adrenoreceptor-blocking drugs.
Waal-Manning, HJ, 1976
)
0.26
" The two drugs caused comparable shifts of the isoproterenol dose-response curve during anesthesia."( Interaction of anesthesia, beta-receptor blockade, and blood loss in dogs with induced myocardial infarction.
Bennett, MJ; Clarke, TN; Foëx, P; Prys-Roberts, C; Roberts, JG; Ryder, WA, 1976
)
0.26
" The different influence of 10 mg propranolol and 20 mg practolol on the stimulating effect of 40 mg furosemide on the PRA can be interpreted as a dosage problem."( [Cyclic AMP and plasma renin activity in renal vein blood after amitryptiline, theophylline, furosemide and beta adrenergic blocking substances (author's transl)].
Klaus, D; Klumpp, F; Lemke, R; Zehner, J, 1976
)
0.5
" The dose-response curves obtained were compared with similar curves previously reported for sotalol, practolol, and atenolol with identical experimental methods."( Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.
Brown, HC; Carruthers, SG; McDevitt, DG; Shanks, RG, 1977
)
0.47
" Specific airway conductance is measured after increasing doses of inhaled salbutamol and the extent to which the dose-response curve is displaced to the right after beta-adrenoceptor blocking drugs is used to assess bronchial beta-adrenoceptor blockade."( Quantitative assessment of bronchial beta-adrenoceptor blockade in man.
Baldwin, CJ; Gribbin, HR; Tattersfield, AE, 1979
)
0.26
" 2 Dose-response and time course experiments revealed that propranolol greatly inhibited microsomal and mitochondrial calcium uptake whereas both acebutolol and practolol showed slight depressant effects."( Comparison of the actions of acebutolol, practolol and propranolol on calcium transport by heart microsomes and mitochondria.
Dhalla, NS; Lee, SL, 1976
)
0.72
" The dose-response curves for the two agonists were parallel, but salbutamol was approximately 1/15 as potent as isoprenaline on a weight basis."( Profile of beta-adrenoceptors in femoral, superior mesenteric and renal vascular beds of dogs.
Taira, N; Yabuuchi, Y; Yamashita, S, 1977
)
0.26
" Isoprenaline, salbutamol and ritodrine caused a dose-dependent reduction of the spontaneous contractions of the pregnant myometrium and a dose-related and parallel shift to the right of the isoprenaline dose-response curve was obtained with butoxamine but not with practolol."( Beta-adrenoceptors in the pregnant and non-pregnant myometrium of the goat and cow.
Larsen, JJ, 1979
)
0.44
"3 Propranolol caused a parallel shift to the right of the noradrenaline dose-response curve which was not changed by phentolamine."( alpha And beta-adrenoceptors in the detrusor muscle and bladder base of the pig and beta-adrenoceptors in the detrusor muscle of man.
Larsen, JJ, 1979
)
0.26
" Log dose-response curves to isoprenaline from spontaneously contracting muscle strips from rabbit uterus have been obtained."( Action of beta-adrenoceptor antagonists on the response to isoprenaline in the oestrogen dominated rabbit uterus.
Nesheim, BI, 1975
)
0.25
" The dose-response curves for isoprenaline were shifted to the right on treatment with practolol."( Distribution and characterization of the adrenoceptors in dog coronary arteries.
Morishita, H, 1979
)
0.48
" Dose-response experiments with six doses of histamine and two doses of the beta2-agonist showed unchanged calculated maximal response and an increase in D50."( Effects of beta2-sympathomimetic on histamine-stimulated gastric acid secretion in dogs.
Gottrup, F; Ornsholt, J, 1979
)
0.26
" Dose-response experiments with 6 doses of pentagastrin and 1 dose of salmefamol showed a decrease in calculated maximal response (CMR) and an unchanged D50."( Inhibition of gastric acid secretion in dogs by a new sympathomimetic drug.
Gottrup, F; Ornsholt, J, 1978
)
0.26
"5 mg/kg, 24 h prior to the experiment) the dose-response curve was not significantly affected by haloperidol, a dopamine vascular receptor antagonist (10(-6)-3X10(-6) M)."( Studies on the positive inotropic effect of dopamine in the guinea-pig heart.
Ledda, F; Maccioni, T; Mantelli, L; Mugelli, A; Torrini, M, 1977
)
0.26
" These doses produced nearly equivalent shifts in isoproterenol-induced chronotropic dose-response curves, indicating equivalent degrees of beta adrenergic blockade."( Superiority of practolol versus propranolol in protection against ventricular fibrillation induced by coronary occlusion.
Gillis, RA; Pearle, DL; Williford, D, 1978
)
0.61
" The dosage was kept unchanged or increased according to the antihypertensive response."( The use of clonidine and practolol in the treatment of hypertension.
Ala-Laurila, P; Pitkäjärvi, T; Ruosteenoja, R; Torsti, P, 1976
)
0.56
" After a two dose trial (Gillam and Prichard, 1966,) demonstrated a dose dependent anti-anginal effect, a log-dose response study demonstrated a progressive reduction in angina attacks as dosage was increased (Prichard and Gillam, 1971)."( Propranolol in the treatment of angina: a review.
Prichard, BN, 1976
)
0.26
"1 The effects of propranolol and practolol, at equivalent myocardial beta-adrenoceptor blocking doses, (as assessed by the degree of shift of isoprenaline dose-response curves) were investigated in anaesthetized greyhounds before and after acute coronary artery ligation."( Comparative effects of propranolol and practolol in the early stages of experimental canine myocardial infarction.
Marshall, RJ; Parratt, JR, 1976
)
0.81
" In the oral study, the peak effect was achieved at a dosage of 200 mg per day (100 mg twice daily) of acebutolol."( Effect of acebutolol, a new beta-receptor antagonist on heart rate and rate-pressure product in normal subjects.
Sharma, PL, 1976
)
0.26
"Serological studies in 22 patients presenting with ocular disease attributable to dosage with the beta-blocking agent practolol revealed a raised incidence of antinuclear antibodies."( Practolol and ocular toxicity. Antibodies in serum and tears.
Garner, A; Rahi, AH, 1976
)
1.91
" Response to practolol was maximum within 15 minutes and was not improved by additional dosage sufficient to raise serum levels."( The use of practolol in supraventricular arrhythmias associated with acute illnesses.
Conn, RD; Pribble, AH, 1975
)
1.01
" In the dosage used in both studies, practolol significantly improved the exercise tolerance and reduced the ischaemic manifestations."( Effects of practolol on exercise tolerance and cardiac haemodynamics and metabolism in patients with coronary artery disease.
Blouin, S; Dagenais, GR; Davies, RO; Marquis, Y; Moisan, A, 1976
)
0.92
"When dose-response curves are replicated, averaging the responses to each dose of drug reduces the slope of the mean curve."( A method for presenting and comparing dose-response curves.
Carpenter, JR, 1986
)
0.27
" and oral dosing has been studied."( The pharmacokinetics of oral and intravenous prenalterol in young, healthy volunteers.
Clarke, AF; Jack, DB; Kendall, MJ; Smith, SR,
)
0.13
" Dose-response curves to a beta agonist, albuterol, were obtained in six normal subjects by measuring specific airway conductance (sGaw) after increasing doses of inhaled albuterol."( Assessment of bronchial beta blockade after oral bevantolol.
Baldwin, CJ; Gribbin, HR; Mackay, AD; Tattersfield, AE, 1981
)
0.26
" Dose-response experiments with five logarithmically increased doses of pentagastrin and one dose of isoprenaline showed unchanged calculated maximum response and an increase in half-maximum acid response."( Effect of isoprenaline on pentagastrin-stimulated gastric acid secretion in dogs with gastric fistula.
Andersen, D; Bech, K; Gottrup, F; Hovendal, CP, 1981
)
0.26
" Because of delayed renal elimination of the drug, daily dosage must be reduced to prevent symptoms of adrenergic stimulation."( Haemodynamic effects of prenalterol in patients on dialysis.
Lustenberger, N, 1982
)
0.26
" What remains to be solved is the dosage level."( Clinical experiences with prenalterol as an antidote to Beta-adrenoceptor blockade.
Kulling, P, 1982
)
0.26
" Moreover, dose-response analysis indicates these salutary improvements can be maximally produced by the small dose of 1 mg obviating the need for larger doses."( The hemodynamic actions of prenalterol in left ventricular failure.
Awan, NA; Evenson, MK; Mason, DT; Needham, KE, 1982
)
0.26
" The dose-response curve with five doses of bethanechol with and without isoprenaline was in accordance with a non-competitive inhibition."( Effect of isoprenaline on bethanechol-stimulated gastric acid secrtion and mucosal blood flow in dogs with gastric fistula.
Bech, K; Hovendal, CP, 1982
)
0.26
" Graded bolus injections of isoprenaline sulphate were given intravenously and control dose-response curves were drawn for the changes in heart rate and blood pressure."( Heart rate and blood pressure responses to intravenous boluses of isoprenaline in the presence of propranolol, practolol and atropine.
Arnold, JM; McDevitt, DG, 1983
)
0.48
"The dose-response curves of the beta-adrenergic agonists isoprenaline (mixed beta 1 and beta 2), prenalterol (beta 1-selective), noradrenaline (more beta 1 than beta 2) and salbutamol (beta 2-selective) were studied on adipose cells of the rat, in vitro."( Characterization of the beta-adrenoceptor of the adipose cell of the rat.
Curtis-Prior, PB; Tan, S, 1983
)
0.27
" The dosage was reduced to 30 mg four times daily because of the development of complex ventricular premature beats."( Effect of prenalterol on orthostatic hypotension in the Shy-Drager syndrome.
Fagard, R; Goovaerts, J; Knockaert, D; Verfaillie, C, 1984
)
0.27
" Similar dose-response curves were found for non-vagotomized dogs with high beta 2-adrenergic tone and dogs with low vagal tone (vagotomy) after pentagastrin and histamine stimulated acid secretion."( Adrenergic receptors and gastric secretion in dogs. Is a "tonic balance" relationship between vagal and beta 2-adrenergic activity a possibility?
Andersen, D; Bech, K; Gottrup, F; Hovendal, C, 1984
)
0.27
" Dose-response experiments with bethanechol and dopamine showed inhibition of a non-competitive type."( Dopaminergic and beta-adrenergic effects on gastric antral motility.
Andersen, D; Bech, K; Gottrup, F; Hovendal, CP, 1984
)
0.27
" The dose-response curves constructed with intra-arterial or intravenous isoprenaline behave similarly in the presence of both atenolol 50 mg and propranolol 40 mg."( Enhancement of physiological finger tremor by intravenous isoprenaline infusions in man: evaluation of its role in the assessment of beta-adrenoceptor antagonists.
Arnold, JM; McDevitt, DG, 1984
)
0.27
" Three days post-AMI the dose-response curve for isoproterenol of right ventricular dP/dtmax was significantly depressed, while the inotropic effect of impromidine was not impaired."( Apparent superiority of H2-receptor stimulation and simultaneous beta-blockade over conventional treatment with beta-sympathomimetic drugs in post-acute myocardial infarction: cardiac effects of impromidine--a new specific H2-receptor agonist-in the survi
Baumann, G; Blömer, H; Felix, SB; Heidecke, CD; Loher, U; Ludwig, L; Riess, G, 1984
)
0.27
" This observation was substantiated from the vertical displacement of dose-response curves from four concentrations of isoprenaline added sequentially."( An apparent preferential antagonism by practolol of the positive inotropic responses of guinea-pig isolated atria to isoprenaline.
Broadley, KJ; Nicholson, CD, 1980
)
0.53
" The dose-response curves for adrenaline did not correspond to simple mass action kinetics and their computer analysis suggests the presence of both beta 1- and beta 2-adrenergic-sensitive adenylate cyclase (58 plus or minus 17% and 42 plus or minus 17% respectively)."( Characteristics of the beta 1-and beta 2-adrenergic-sensitive adenylate cyclases in glial cell primary cultures and their comparison with beta 2-adrenergic-sensitive adenylate cyclase of meningeal cells.
Bockaert, J; Ebersolt, C; Perez, M; Vassent, G, 1981
)
0.26
" Satisfactory dose-response curves could be constructed for the isoprenaline enhanced increases in finger tremor."( An assessment of physiological finger tremor as an indicator of beta-adrenoceptor function.
Arnold, JM; McDevitt, DG, 1983
)
0.27
" Prenalterol dosage was simple and could be guided by blood pressure response."( Massive metoprolol poisoning treated with prenalterol.
Hulting, J; Wallin, CJ, 1983
)
0.27
" Dose-response studies in five patients showed dose-dependent increments in hemodynamic variables, while hormonal changes plateaued at the second dose level."( Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure.
Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG, 1983
)
0.27
" The two beta-adrenoceptor antagonists were given at two dose levels, practolol (200 mg and 400 mg) daily, and metoprolol (100 mg and 200 mg) daily, in a twice-daily dosage schedule, at 12 h intervals, for 17 days."( The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics.
Formgren, H, 1976
)
0.78
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
beta-adrenergic antagonistAn agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
propanolamine
ethanolamines
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
acetamidesCompounds with the general formula RNHC(=O)CH3.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Practolol Action Pathway478

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency13.33320.000714.592883.7951AID1259392
Histone H2A.xCricetulus griseus (Chinese hamster)Potency61.93150.039147.5451146.8240AID1224896
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.10000.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1209455; AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-1 adrenergic receptor Cavia porcellus (domestic guinea pig)Kd1.87470.00000.53588.3176AID39950; AID42040; AID42206; AID42207; AID42210; AID42217; AID79652
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Beta-2 adrenergic receptorHomo sapiens (human)Kd18.85320.00000.62888.9130AID1798580; AID41154; AID41320
Beta-1 adrenergic receptorHomo sapiens (human)Kd18.85320.00010.803910.0000AID1798580; AID41154; AID41320
Beta-3 adrenergic receptorHomo sapiens (human)Kd18.85320.00010.76318.9130AID1798580; AID41154; AID41320
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Beta-1 adrenergic receptorRattus norvegicus (Norway rat)Kd0.33880.00140.06010.3910AID1136427
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd4.46680.00012.29338.5114AID40869
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Beta-2 adrenergic receptorCanis lupus familiaris (dog)Kd0.18620.18620.18620.1862AID41481
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Beta-2 adrenergic receptor Bos taurus (cattle)Kd20.41700.00061.47759.1200AID40694
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)Kd4.46680.00020.54774.4668AID40869
GABA theta subunitRattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Kd4.46680.00020.56294.4668AID40869
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2A adrenergic receptorHomo sapiens (human)Kapp313.00000.01700.03700.0930AID1123537
Beta-2 adrenergic receptorRattus norvegicus (Norway rat)Kapp313.00000.01700.03700.0930AID1123537
Alpha-2B adrenergic receptorHomo sapiens (human)Kapp313.00000.01700.03700.0930AID1123537
Beta-1 adrenergic receptorRattus norvegicus (Norway rat)Kapp18.00000.00770.01190.0150AID1123536
Alpha-2C adrenergic receptorHomo sapiens (human)Kapp313.00000.01700.03700.0930AID1123537
Alpha-1D adrenergic receptorHomo sapiens (human)Kapp313.00000.01700.03700.0930AID1123537
Alpha-1A adrenergic receptorHomo sapiens (human)Kapp313.00000.01700.03700.0930AID1123537
Alpha-1B adrenergic receptorHomo sapiens (human)Kapp313.00000.01700.03700.0930AID1123537
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (136)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorCanis lupus familiaris (dog)
regulation of smooth muscle contractionBeta-2 adrenergic receptorCanis lupus familiaris (dog)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorCanis lupus familiaris (dog)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorCanis lupus familiaris (dog)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorCanis lupus familiaris (dog)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorCanis lupus familiaris (dog)
positive regulation of lipophagyBeta-2 adrenergic receptorCanis lupus familiaris (dog)
receptor-mediated endocytosisBeta-2 adrenergic receptor Bos taurus (cattle)
regulation of smooth muscle contractionBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of MAPK cascadeBeta-2 adrenergic receptor Bos taurus (cattle)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of autophagosome maturationBeta-2 adrenergic receptor Bos taurus (cattle)
positive regulation of lipophagyBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorCanis lupus familiaris (dog)
protein homodimerization activityBeta-2 adrenergic receptorCanis lupus familiaris (dog)
norepinephrine bindingBeta-2 adrenergic receptorCanis lupus familiaris (dog)
beta2-adrenergic receptor activityBeta-2 adrenergic receptor Bos taurus (cattle)
protein homodimerization activityBeta-2 adrenergic receptor Bos taurus (cattle)
norepinephrine bindingBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneBeta-2 adrenergic receptorMus musculus (house mouse)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorCanis lupus familiaris (dog)
Golgi apparatusBeta-2 adrenergic receptorCanis lupus familiaris (dog)
receptor complexBeta-2 adrenergic receptorCanis lupus familiaris (dog)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
early endosomeBeta-2 adrenergic receptor Bos taurus (cattle)
Golgi apparatusBeta-2 adrenergic receptor Bos taurus (cattle)
receptor complexBeta-2 adrenergic receptor Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (213)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID191849Compound was tested for antagonism of Ventricular Fibrilloflutter (VF) evoked by coronary artery ligation in the rat measured at 5 mg/kg dose1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Antiarrhythmic activity of 17 beta-aminoestratrienes. Comparison of 3-ols and 3-acetates with the corresponding 3-(3-amino-2-hydroxypropyl) ethers.
AID42210Cardioselectivity for the beta-1 adrenergic receptor was determined against isoprenaline (antagonism) in isolated guinea pig trachea1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.
AID176761In vivo beta adrenergic receptor blocking potency was determined by inhibition of tachycardia in rat1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
beta-adrenergic blocking agents. 24. Heterocyclic substituted 1-(aryloxy)-3-[[(amido)alkyl]amino]propan-2-ols.
AID40869In vitro beta-2 adrenergic receptor activity was determined by measuring inhibition of the isoproterenol induced relaxation in isolated guinea pig tracheal chains contracted with PGF2-alpha1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.
AID199130Ki value was determined by accumulation of c-AMP in S-49 mouse lymphoma cells (Beta2).1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and beta-adrenergic antagonist activity of stereoisomeric practolol and propranolol derivatives.
AID191846Compound was tested for antagonism of Ventricular Fibrilloflutter (VF) evoked by coronary artery ligation in the rat measured at 10 mg/kg dose1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Antiarrhythmic activity of 17 beta-aminoestratrienes. Comparison of 3-ols and 3-acetates with the corresponding 3-(3-amino-2-hydroxypropyl) ethers.
AID1136812In-vivo beta-adrenergic blocking activity activity in iv dosed mongrel dog assessed as blockade of isoproterenol-induced tachycardia by measuring heart rate1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
beta-Adrenergic blocking agents with acute antihypertensive activity.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID41477Apparent dissociation constant towards beta-2 adrenergic receptor in rat lung membranes using (2-6)x10E-9M of [3AH]-DHA in the presence or absence of 10e-5 M (+/-) propranolol.1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Beta-adrenoceptor antagonist activity of bivalent ligands. 1. Diamide analogues of practolol.
AID41903Beta adrenoceptor blocking potency was estimated by inhibition of 50% of the tachycardia produced by a submaximal dose of the isoproterenol (0.2ug/kg, intravenously)1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Beta-adrenergic blocking agents. 21. threo-1-(Aryloxy)-3-(alkylamino)butan-2-ols.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID41481Cardioselectivity for the beta-2 adrenergic receptor was determined against isoprenaline (antagonism) in isolated rat atria1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.
AID47945Beta-adrenoceptor blocking potency in cat as dose causing 50% inhibition of the tachycardia produced by 0.2 ug/kg iv of isoproterenol1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Beta-adrenergic blocking agents. 19. 1-Phenyl-2-[[(substituted-amido)alkyl]amino]ethanols.
AID184112Maximum increase in heart rate evoked by isoprenaline.1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Antiarrhythmic activity of 17 beta-aminoestratrienes. Comparison of 3-ols and 3-acetates with the corresponding 3-(3-amino-2-hydroxypropyl) ethers.
AID18847Percent of drug absorbed by human intestine after oral administration2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.
AID25572Dissociation constant of the compound1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.
AID21254Mono layer permeability of human intestinal Caco-2 cells1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.
AID1135311In vivo inhibition of beta-2 adrenergic receptor in cat assessed as inhibition of isoproterenol-induced vasodepressor response at ED50 administered as 30 mins of infusion measured at 30 mins relative to control1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Beta-Adrenergic blocking agents. 15. 1-Substituted ureidophenoxy-3-amino-2-propanols.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID218845Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID15120Percent of the drug absorbed after administration to humans was determined1999Journal of medicinal chemistry, May-20, Volume: 42, Issue:10
Molecular hashkeys: a novel method for molecular characterization and its application for predicting important pharmaceutical properties of molecules.
AID603955In-vivo blood to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1123537Displacement of [3H]DHA from beta2 adrenergic receptor in rat lung muscle by competitive binding assay1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1147036Ratio of in vivo beta-2 adrenergic receptor blocking activity in iv dosed cat assessed as half dose required for desensitizing isoproterenol-induced diastolic hypotensive response to in vivo beta-1 adrenergic receptor blocking activity in iv dosed cat ass1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
A new series of cardioselective adrenergic beta-receptor blocking compounds. 1-(2-Acyl-4-acylaminophenoxy)-3-isopropylaminopropan-2-ols.
AID41889Tested for intrinsic sympathomimetic activity (ISA); Antagonist with partial agonistic properties1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID1091956Apparent hydrophobicity, log D of the compound in Octanol-buffer2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1135310In vivo inhibition of beta-1 adrenergic receptor in cat assessed as inhibition of isoproterenol-induced tachycardia administered as 30 mins of infusion measured at 30 mins by cardiotachometer1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Beta-Adrenergic blocking agents. 15. 1-Substituted ureidophenoxy-3-amino-2-propanols.
AID1123536Displacement of [3H]DHA from beta1 adrenergic receptor in rat ventricular muscle by competitive binding assay1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols.
AID237585Tested for fraction of oral dose absorbed orally in humans2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID193776Effect on heart rate before isoprenaline induced tachycardia in the anesthetized rat at 5 mg/kg dose1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Antiarrhythmic activity of 17 beta-aminoestratrienes. Comparison of 3-ols and 3-acetates with the corresponding 3-(3-amino-2-hydroxypropyl) ethers.
AID218848Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID231957Ratio of dissociation constant KD' of rat lung to KD' of rat heart1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Beta-adrenoceptor antagonist activity of bivalent ligands. 1. Diamide analogues of practolol.
AID47944Beta-adrenergic blocking potency to inhibit tachycardia in anesthetized cats1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
beta-Adrenergic blocking agents. 23. 1-[Substituted-amido)phenoxy]-3-[[(substituted-amido)alkyl]amino] propan-2-ols.
AID41319Inhibition of beta adrenergic receptor activity in isolated guinea pig atria against isoprenaline at 4E-8M1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Conformational effects on the activity of drugs. 10. Synthesis, conformation, and pharmacological properties of 1-(2,5-dimethoxyphenyl)-2-aminoethanols and their morpholine analogues.
AID1146171In vivo antagonist activity at beta-1 adrenergic receptor in cat assessed as inhibition of isoproterenol-induced tachycardia administered as infusion for 30 mins by cardiotachometric analysis1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
beta-Adrenergic blocking agents. 16. 1-(Acylaminomethyl-, ureidomethyl-, and ureidoethylphenoxy)-3-amino-2-propanols.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1145386Partition coefficient, log P of the compound by shake-flask technique1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID48537Percent inhibition of vasopressor response1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Beta-adrenergic blocking agents. 21. threo-1-(Aryloxy)-3-(alkylamino)butan-2-ols.
AID42206Antagonist activity against beta-1 adrenergic receptor in isolated guinea pig atria1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Role of the (acyloxy)methyl moiety in eliciting the adrenergic beta-blocking activity of 3-(acyloxy)propanolamines.
AID1136325Intrinsic activity at beta1 adrenoceptor in guinea pig atrium after 20 mins relative to control1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Methoxyphenylethanolamines, potential beta-adrenergic blocking agents.
AID1136132Potency ratio for in vivo inhibition of beta-1 adrenoceptor in vagotomized cat assessed as inhibition of isoproterenol-induced tachycardia to in vivo inhibition of beta-2 adrenoceptor in chloralose-anesthetized vagotomized cat assessed as inhibition of is1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Alteration of relative affinities toward myocardial and vascular beta adrenoceptors induced by side-chain substitution of aryloxypropanolamines.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID41005Specific antagonistic activity difference against beta-2 adrenergic receptor of isolated guinea pig tracheal strips1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives.
AID42218In vitro beta-1 adrenergic receptor activity was determined via inhibition of the positive chronotropic actions of isoproterenol in isolated guinea pig atrial preparations1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.
AID1147034In vivo beta-1 adrenergic receptor blocking activity in iv dosed cat assessed as half dose required for desensitizing isoproterenol-induced tachycardia after 3.5 mins1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
A new series of cardioselective adrenergic beta-receptor blocking compounds. 1-(2-Acyl-4-acylaminophenoxy)-3-isopropylaminopropan-2-ols.
AID1136327Intrinsic activity at beta2 adrenoceptor in guinea pig trachea after 20 mins1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Methoxyphenylethanolamines, potential beta-adrenergic blocking agents.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID41487Selectivity towards beta-2 adrenergic receptor; Nonselective towards beta-2 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID1136813In-vivo beta-adrenergic blocking activity activity in iv dosed mongrel dog assessed as blockade of isoproterenol-induced bronchoconstriction by measuring pulmonary pressure1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
beta-Adrenergic blocking agents with acute antihypertensive activity.
AID231333Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1123538Cardio selectivity ratio of Kapp for beta2 adrenergic receptor in rat lung muscle to Kapp for beta1 adrenergic receptor in rat ventricular muscle1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols.
AID79652Ability to block Beta-1 adrenergic receptor in guinea pig right atria preparation at a duration of 40 min1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.
AID42040Antagonist activity of compound against Beta-1 adrenergic receptor in isolated guinea pig left atria1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
2-Benzodioxinylaminoethanols: a new class of beta-adrenergic blocking and antihypertensive agents.
AID1091957Apparent permeability of the compound by PAMPA2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1091958Hydrophobicity, log P of the compound in octanol-water by shaking-flask method2011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID40719Antagonist activity of compound against Beta-2 adrenergic receptor in isolated guinea pig trachea; Inactive at a concentration of 10e-4 M/L1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
2-Benzodioxinylaminoethanols: a new class of beta-adrenergic blocking and antihypertensive agents.
AID26525Distribution coefficient measured in Octanol/buffer (0.15 M KCl)1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.
AID1136130In vivo inhibition of beta-1 adrenoceptor in vagotomized cat assessed as inhibition of isoproterenol-induced tachycardia1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Alteration of relative affinities toward myocardial and vascular beta adrenoceptors induced by side-chain substitution of aryloxypropanolamines.
AID1145387Partition coefficient, log P of the compound by HPLC analysis1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID196739Biological activity in vitro, Ki value was determined by accumulation of c-AMP in rat fat cells (Beta1).1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and beta-adrenergic antagonist activity of stereoisomeric practolol and propranolol derivatives.
AID233866Selectivity determined by expression 10[pA2(atria) - pA2 (trachea)] in guinea pig1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
[(Arylcarbonyl)oxy]propanolamines. 1. Novel beta-blockers with ultrashort duration of action.
AID228305Cardioselectivity expressed as antilog of pA2 (atria)-pA2 (trachea).1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.
AID42204Antagonist activity against beta-1 adrenergic receptor in isolated guinea pig atria1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Role of the (acyloxy)methyl moiety in eliciting the adrenergic beta-blocking activity of 3-(acyloxy)propanolamines.
AID39955Specific antagonistic activity difference against beta-1 adrenergic receptor of isolated guinea pig atria1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID28399Cellular permeability (Pc) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID193682Mean change in heart rate recorded 14 min after the administration of compound.1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Antiarrhythmic activity of 17 beta-aminoestratrienes. Comparison of 3-ols and 3-acetates with the corresponding 3-(3-amino-2-hydroxypropyl) ethers.
AID47973In vivo beta adrenoceptor blocking potency was determined by inhibition of tachycardia in cat1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
beta-adrenergic blocking agents. 24. Heterocyclic substituted 1-(aryloxy)-3-[[(amido)alkyl]amino]propan-2-ols.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID29844Fraction absorbed after oral administration in humans2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID42207Antagonistic activity against beta-1 adrenergic receptor of isolated guinea pig atria1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives.
AID1136131In vivo inhibition of beta-2 adrenoceptor in chloralose-anesthetized vagotomized cat assessed as inhibition of isoproterenol-induced fall in diastolic pressure1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Alteration of relative affinities toward myocardial and vascular beta adrenoceptors induced by side-chain substitution of aryloxypropanolamines.
AID233918Selectivity index is the ratio of tracheal to atrial pA2 values1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Role of the (acyloxy)methyl moiety in eliciting the adrenergic beta-blocking activity of 3-(acyloxy)propanolamines.
AID48526Beta-adrenoceptor blocking potency in cat, measured as the degree (percent) of blockade of the vasopressor response at the dose level1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Beta-adrenergic blocking agents. 20. (3-Hydroxyprop-1-enyl)-substituted 1-(aryloxy)-3-(alkylamino)propan-2-ols.
AID196740Relative potency(RP) was determined for the biological activity determined in rat fat cells (Beta1)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and beta-adrenergic antagonist activity of stereoisomeric practolol and propranolol derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID41320Inhibition of beta adrenergic receptor on isolated guinea pig atria against isoprenaline at 4E-8M1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Conformational effects on the activity of drugs. 10. Synthesis, conformation, and pharmacological properties of 1-(2,5-dimethoxyphenyl)-2-aminoethanols and their morpholine analogues.
AID1147035In vivo beta-2 adrenergic receptor blocking activity in iv dosed cat assessed as half dose required for desensitizing isoproterenol-induced diastolic hypotensive response after 3.5 mins1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
A new series of cardioselective adrenergic beta-receptor blocking compounds. 1-(2-Acyl-4-acylaminophenoxy)-3-isopropylaminopropan-2-ols.
AID41156In vitro blocking of beta adrenergic receptor in guinea pig trachea1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
[(Arylcarbonyl)oxy]propanolamines. 1. Novel beta-blockers with ultrashort duration of action.
AID1136811In-vivo beta-adrenergic blocking activity in iv dosed mongrel dog assessed as blockade of isoproterenol-induced hypotension by measuring mean arterial pressure1979Journal of medicinal chemistry, Jun, Volume: 22, Issue:6
beta-Adrenergic blocking agents with acute antihypertensive activity.
AID234583Bronchoselectivity as antilog difference between pA2 for tracheal beta-2 and atrial beta-1 assays1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID40877Ability to block Beta-2 adrenergic receptor in guinea pig trachea preparation1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.
AID48535In vivo beta adrenergic blocking potency was determined by inhibition of depressor response produced by isoproterenol (0.2 mg/kg iv) in cat preparation1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Beta-adrenergic blocking agents. 22. 1-Phenoxy-3-[[(substituted-amido) alkyl]amino]-2-propanols.
AID1146172In vivo antagonist activity at beta-2 adrenergic receptor in cat assessed as inhibition of vasodepressor response administered as infusion for 30 mins relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
beta-Adrenergic blocking agents. 16. 1-(Acylaminomethyl-, ureidomethyl-, and ureidoethylphenoxy)-3-amino-2-propanols.
AID193879Change in systolic blood pressure in anesthetized spontaneous hypertensive rats when 20 mg/kg of compound was administered intravenously1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
2-Benzodioxinylaminoethanols: a new class of beta-adrenergic blocking and antihypertensive agents.
AID1136427Antagonist activity at beta1 adrenergic receptor in isolated rat atria1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Cardioselectivity as a function of molecular structure in beta-adrenoceptor blocking agents of the 1-(para-substituted aryloxy)-3-(isopropylamino)propan-2-ol type.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID28392Apparent permeability coefficient (Papp) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID40863Antagonistic activity against beta-2 adrenergic receptor of isolated guinea pig tracheal strips1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives.
AID40404Apparent dissociation constant towards beta-1 adrenergic receptor in rat heart membranes using (2-6)x10E-9M of [3AH]-DHA in the presence or absence of 10e-5 M (+/-) propranolol.1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Beta-adrenoceptor antagonist activity of bivalent ligands. 1. Diamide analogues of practolol.
AID1136428Antagonist activity at beta2 adrenergic receptor in isolated rat stomach fundus1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Cardioselectivity as a function of molecular structure in beta-adrenoceptor blocking agents of the 1-(para-substituted aryloxy)-3-(isopropylamino)propan-2-ol type.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1147037Antiarrhythmic activity in iv dosed dog assessed as dose required for reversal of ouabain-induced cardiac arrhythmia1976Journal of medicinal chemistry, Mar, Volume: 19, Issue:3
A new series of cardioselective adrenergic beta-receptor blocking compounds. 1-(2-Acyl-4-acylaminophenoxy)-3-isopropylaminopropan-2-ols.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1136332Selectivity ratio for beta1 adrenoceptor in guinea pig atrium over beta2 adrenoceptor in guinea pig trachea1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Methoxyphenylethanolamines, potential beta-adrenergic blocking agents.
AID176310Beta-adrenoceptor blocking potency was estimated in vivo by blockade of the isoproterenol tachycardia response in rat; ND means no data1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Beta-adrenergic blocking agents. 19. 1-Phenyl-2-[[(substituted-amido)alkyl]amino]ethanols.
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID48524In vivo beta-adrenoceptor blocking potency in cat (expressed as total dose infused over a period of 30 minutes causing 50% inhibition of the tachycardia by iv administration)1980Journal of medicinal chemistry, Oct, Volume: 23, Issue:10
Beta-adrenergic blocking agents. 20. (3-Hydroxyprop-1-enyl)-substituted 1-(aryloxy)-3-(alkylamino)propan-2-ols.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID47972In vivo beta adrenergic blocking potency was determined by inhibition of tachycardia produced by isoproterenol (0.2 mg/kg iv) in cat preparation1982Journal of medicinal chemistry, Nov, Volume: 25, Issue:11
Beta-adrenergic blocking agents. 22. 1-Phenoxy-3-[[(substituted-amido) alkyl]amino]-2-propanols.
AID11361351-Octanol-phosphate buffer apparent partition coefficient, log P of the compound at pH 7.41978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Alteration of relative affinities toward myocardial and vascular beta adrenoceptors induced by side-chain substitution of aryloxypropanolamines.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID230147The cardioselectivity ratio was obtained by taking the antilog of (pA2(beta-1)-pA2(beta2))1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.
AID39950Ability to block Beta-1 adrenergic receptor in guinea pig right atria preparation1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.
AID40864Antagonist activity against beta-2 adrenergic receptor in isolated guinea pig trachea1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Role of the (acyloxy)methyl moiety in eliciting the adrenergic beta-blocking activity of 3-(acyloxy)propanolamines.
AID40862Antagonist activity against beta-2 adrenergic receptor in isolated guinea pig trachea1987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Role of the (acyloxy)methyl moiety in eliciting the adrenergic beta-blocking activity of 3-(acyloxy)propanolamines.
AID232998Degree of Selectivity measured as the antilog of pA2 atria-pA2 trachea1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.
AID40694Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID41154In Vitro inhibition of the beta adrenergic receptor in guinea pig atria1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
[(Arylcarbonyl)oxy]propanolamines. 1. Novel beta-blockers with ultrashort duration of action.
AID192643Dose required to induce at least 50% inhibition of the isoprenaline-induced effect, administered intravenously1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
2-Benzodioxinylaminoethanols: a new class of beta-adrenergic blocking and antihypertensive agents.
AID42217Activity at beta-1 adrenergic receptor1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Computer-aided mapping of the beta-adrenoceptor. 1. Explanation for effect of para substitution on blocking activity at the beta-1-adrenoceptor.
AID1091955Dissociation constant, pKa of the compound at pH 7.32011Journal of agricultural and food chemistry, Apr-13, Volume: 59, Issue:7
Importance of physicochemical properties for the design of new pesticides.
AID12234881-Octanol-water distribution coefficient, log D of the compound at pH 7.42012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID178580Effective dose that antagonized arrhythmias evoked by coronary artery ligation in the rat was measured at 5 mg/kg dose1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Antiarrhythmic activity of 17 beta-aminoestratrienes. Comparison of 3-ols and 3-acetates with the corresponding 3-(3-amino-2-hydroxypropyl) ethers.
AID48536In vivo beta-adrenergic blocking potency to inhibit vasopressor response in anesthetized cats1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
beta-Adrenergic blocking agents. 23. 1-[Substituted-amido)phenoxy]-3-[[(substituted-amido)alkyl]amino] propan-2-ols.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1136326Antagonist activity at beta2 adrenoceptor in guinea pig trachea assessed as inhibition of isoproterenol-induced response after 20 mins1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Methoxyphenylethanolamines, potential beta-adrenergic blocking agents.
AID48538Percentage inhibition of depressor response in cat was determined1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Beta-adrenergic blocking agents. 19. 1-Phenyl-2-[[(substituted-amido)alkyl]amino]ethanols.
AID193771Effect on heart rate after isoprenaline induced tachycardia in the anesthetized rat at 5 mg/kg dose1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Antiarrhythmic activity of 17 beta-aminoestratrienes. Comparison of 3-ols and 3-acetates with the corresponding 3-(3-amino-2-hydroxypropyl) ethers.
AID40686Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1136324Antagonist activity at beta1 adrenoceptor in guinea pig atrium assessed as inhibition of isoproterenol-induced response after 20 mins1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
2-Methoxyphenylethanolamines, potential beta-adrenergic blocking agents.
AID40537Selectivity for beta-1 adrenergic receptor1988Journal of medicinal chemistry, Nov, Volume: 31, Issue:11
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
AID40865Antagonistic activity against beta-2 adrenergic receptor on isolated guinea pig tracheal strips1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives.
AID42205Antagonistic activity against beta-1 adrenergic receptor of isolated guinea pig atria1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives.
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID191848Antagonism of Ventricular Fibrilloflutter (VF) evoked by coronary artery ligation in the rat measured at 2 mg/kg dose1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Antiarrhythmic activity of 17 beta-aminoestratrienes. Comparison of 3-ols and 3-acetates with the corresponding 3-(3-amino-2-hydroxypropyl) ethers.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID48540The compound was evaluated for inhibition of depressor response1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
beta-adrenergic blocking agents. 24. Heterocyclic substituted 1-(aryloxy)-3-[[(amido)alkyl]amino]propan-2-ols.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID193868Change in diastolic blood pressure in anesthetized spontaneous hypertensive rats when 20 mg/kg of compound was administered intravenously1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
2-Benzodioxinylaminoethanols: a new class of beta-adrenergic blocking and antihypertensive agents.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID199131Potency relative to practolol determined in S-49 mouse lymphoma cells (Beta2).1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and beta-adrenergic antagonist activity of stereoisomeric practolol and propranolol derivatives.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1136429Selectivity ratio of beta1 adrenergic receptor in isolated rat atria to beta2 adrenergic receptor in isolated rat stomach fundus1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Cardioselectivity as a function of molecular structure in beta-adrenoceptor blocking agents of the 1-(para-substituted aryloxy)-3-(isopropylamino)propan-2-ol type.
AID193781Effect on heart rate on 1 min post isoprenaline induced tachycardia in the anesthetized rat at 5.0 mg/kg dose.1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Antiarrhythmic activity of 17 beta-aminoestratrienes. Comparison of 3-ols and 3-acetates with the corresponding 3-(3-amino-2-hydroxypropyl) ethers.
AID193230Duration of action of compound was determined for antihypertensive action in rats1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
2-Benzodioxinylaminoethanols: a new class of beta-adrenergic blocking and antihypertensive agents.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID17985803H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: \\The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.\\2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)1999European journal of pharmacology, Feb-19, Volume: 367, Issue:2-3
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,475)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901376 (93.29)18.7374
1990's40 (2.71)18.2507
2000's28 (1.90)29.6817
2010's24 (1.63)24.3611
2020's7 (0.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.61 (24.57)
Research Supply Index7.46 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials177 (11.30%)5.53%
Trials0 (0.00%)5.53%
Reviews75 (4.79%)6.00%
Reviews0 (0.00%)6.00%
Case Studies91 (5.81%)4.05%
Case Studies0 (0.00%)4.05%
Observational1 (0.06%)0.25%
Observational0 (0.00%)0.25%
Other1,222 (78.03%)84.16%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]